[go: up one dir, main page]

MX2018008105A - Compuestos inhibidores de metaloenzima. - Google Patents

Compuestos inhibidores de metaloenzima.

Info

Publication number
MX2018008105A
MX2018008105A MX2018008105A MX2018008105A MX2018008105A MX 2018008105 A MX2018008105 A MX 2018008105A MX 2018008105 A MX2018008105 A MX 2018008105A MX 2018008105 A MX2018008105 A MX 2018008105A MX 2018008105 A MX2018008105 A MX 2018008105A
Authority
MX
Mexico
Prior art keywords
metaloenzima
inhibiting compounds
metalloenzymes
mediated
symptoms
Prior art date
Application number
MX2018008105A
Other languages
English (en)
Other versions
MX376201B (es
Inventor
R Shaver Sammy
J Hoekstra William
m yates Christopher
Original Assignee
Vps 3 Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vps 3 Inc filed Critical Vps 3 Inc
Publication of MX2018008105A publication Critical patent/MX2018008105A/es
Publication of MX376201B publication Critical patent/MX376201B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente invención describe compuestos que tienen actividad moduladora de metaloenzima, y métodos para tratar enfermedades, trastornos o síntomas de los mismos mediadas por dichas metaloenzimas.
MX2018008105A 2015-12-30 2016-12-29 Compuestos inhibidores de metaloenzima. MX376201B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562273167P 2015-12-30 2015-12-30
PCT/US2016/069217 WO2017117393A1 (en) 2015-12-30 2016-12-29 Metalloenzyme inhibitor compounds

Publications (2)

Publication Number Publication Date
MX2018008105A true MX2018008105A (es) 2018-11-12
MX376201B MX376201B (es) 2025-03-07

Family

ID=59225927

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018008105A MX376201B (es) 2015-12-30 2016-12-29 Compuestos inhibidores de metaloenzima.

Country Status (12)

Country Link
US (1) US10464922B2 (es)
EP (1) EP3397629B1 (es)
JP (1) JP6803923B2 (es)
KR (1) KR102240920B1 (es)
CN (1) CN108779094B (es)
AU (1) AU2016380349B2 (es)
BR (1) BR112018013522A2 (es)
CA (1) CA3006469C (es)
EA (1) EA038421B1 (es)
MX (1) MX376201B (es)
TW (1) TWI623528B (es)
WO (1) WO2017117393A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015231220B2 (en) 2014-03-19 2019-04-04 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Antifungal compound process
US9914726B2 (en) 2014-03-19 2018-03-13 Vps-3, Inc. 2-(2,4-difluorophenyl)-1,1-difluoro-1-(5-substituted-pyridin-2-yl)-3-(1H-tetrazol-1-yl)propan-2-ols and processes for their preparation
JP6633539B2 (ja) 2014-03-19 2020-01-22 ダウ アグロサイエンシィズ エルエルシー ２−（２，４−ジフルオロフェニル）−１，１−ジフルオロ−１−（５−置換−ピリジン−２−イル）−３−（１ｈ−テトラゾール−１−イル）プロパン−２−オールおよびその調製工程
EP3119745B1 (en) 2014-03-19 2020-08-05 Mycovia Pharmaceuticals, Inc. Antifungal compound process
AU2015231234B2 (en) 2014-03-19 2019-04-04 Mycovia Pharmaceuticals, Inc. Antifungal compound process
BR112016021282A8 (pt) 2014-03-19 2021-07-20 The Us Secretary Department Of Health & Human Services processos para a preparação de compostos antifúngicos e os referidos compostos
JP6518683B2 (ja) 2014-03-19 2019-05-22 ヴィアメット ファーマスーティカルズ（エヌシー），インコーポレイテッド 抗真菌化合物の調製方法
AU2015231216B2 (en) 2014-03-19 2019-04-04 Mycovia Pharmaceuticals, Inc. Antifungal compound process
JP2017514790A (ja) 2014-03-19 2017-06-08 ヴィアメット ファーマスーティカルズ，インコーポレイテッド 抗真菌化合物の調製方法
AU2016323782B2 (en) 2015-09-18 2020-11-26 Nqp 1598, Ltd. Antifungal compound process
WO2019182743A1 (en) * 2018-03-20 2019-09-26 Innocrin Pharmaceuticals, Inc. Compositions for the treatment of brain tumors
WO2020077197A1 (en) 2018-10-11 2020-04-16 Innocrin Pharmaceuticals, Inc. Compositions for the treatment of brain tumors
EP4320127A1 (en) 2021-04-05 2024-02-14 Halia Therapeutics, Inc. Nek7 inhibitors
CN113444131B (zh) * 2021-06-24 2022-10-21 鲁东大学 N-乙酰氨基葡萄糖类化合物及其制备方法和应用
WO2023069613A1 (en) * 2021-10-20 2023-04-27 Ohio State Innovation Foundation Arylimidamides for use in treatment of cancers
CN115466227B (zh) * 2022-06-30 2024-07-19 杭州国瑞生物科技有限公司 一种3-(氯甲基)-1-甲基-1h-1,2,4-三唑盐酸盐的制备方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4921475A (en) 1983-08-18 1990-05-01 Drug Delivery Systems Inc. Transdermal drug patch with microtubes
US5087240A (en) 1983-08-18 1992-02-11 Drug Delivery Systems Inc. Transdermal drug patch with conductive fibers
US4738851A (en) 1985-09-27 1988-04-19 University Of Iowa Research Foundation, Inc. Controlled release ophthalmic gel formulation
US5163899A (en) 1987-03-20 1992-11-17 Drug Delivery Systems Inc. Transdermal drug delivery system
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
GB8804164D0 (en) 1988-02-23 1988-03-23 Tucker J M Bandage for administering physiologically active compound
US4882150A (en) 1988-06-03 1989-11-21 Kaufman Herbert E Drug delivery system
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5088977A (en) 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
US5521222A (en) 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
EP0431519B1 (en) 1989-12-04 1994-06-15 G.D. Searle & Co. System for transdermal albuterol administration
US5077033A (en) 1990-08-07 1991-12-31 Mediventures Inc. Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5352456A (en) 1991-10-10 1994-10-04 Cygnus Therapeutic Systems Device for administering drug transdermally which provides an initial pulse of drug
JPH07502219A (ja) 1991-12-18 1995-03-09 ミネソタ　マイニング　アンド　マニュファクチャリング　カンパニー 多重層型バリアー構造体
EP0553769B1 (de) 1992-01-29 1996-01-03 FRANZ VÖLKL GmbH & CO. SKI UND TENNIS SPORTARTIKELFABRIK KG Ballspielschläger, insbesondere Tennisschläger
PT765314E (pt) * 1994-06-15 2003-09-30 Otsuka Pharma Co Ltd Derivados benzo-heterociclicos uteis como moduladores da vasopressina ou da oxitocina
IL114193A (en) 1994-06-20 2000-02-29 Teva Pharma Ophthalmic pharmaceutical compositions based on sodium alginate
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
IT1283911B1 (it) 1996-02-05 1998-05-07 Farmigea Spa Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
US6261547B1 (en) 1998-04-07 2001-07-17 Alcon Manufacturing, Ltd. Gelling ophthalmic compositions containing xanthan gum
US6197934B1 (en) 1998-05-22 2001-03-06 Collagenesis, Inc. Compound delivery using rapidly dissolving collagen film
AUPP999799A0 (en) * 1999-04-27 1999-05-20 Fujisawa Pharmaceutical Co., Ltd. New compound
CN100415234C (zh) 2001-04-03 2008-09-03 先灵公司 生物利用度提高的抗真菌组合物
KR101379370B1 (ko) 2010-04-24 2014-03-28 비아멧 파마슈티컬즈, 인코포레이티드 금속효소 억제제 화합물
KR102104125B1 (ko) * 2011-04-21 2020-05-29 재단법인 한국파스퇴르연구소 소염 화합물
BR112014017799A8 (pt) 2012-01-20 2017-07-11 Viamet Pharmaceuticals Inc Compostos inibidores de metaloenzima
IN2014DN06792A (es) * 2012-01-20 2015-05-22 Viamet Pharmaceuticals Inc
EP3008051A4 (en) * 2013-06-12 2017-03-01 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
US9802914B2 (en) * 2014-03-19 2017-10-31 Viamet Pharmaceuticals, Inc. Antifungal compound process

Also Published As

Publication number Publication date
EP3397629B1 (en) 2023-04-19
TW201734000A (zh) 2017-10-01
CN108779094B (zh) 2021-11-16
CA3006469C (en) 2023-01-10
AU2016380349A1 (en) 2018-06-14
BR112018013522A2 (pt) 2018-12-11
CN108779094A (zh) 2018-11-09
MX376201B (es) 2025-03-07
EP3397629A1 (en) 2018-11-07
JP2019502755A (ja) 2019-01-31
US20190016700A1 (en) 2019-01-17
CA3006469A1 (en) 2017-07-06
WO2017117393A1 (en) 2017-07-06
KR102240920B1 (ko) 2021-04-16
KR20180099845A (ko) 2018-09-05
EA201891539A1 (ru) 2018-12-28
EP3397629A4 (en) 2019-06-05
AU2016380349B2 (en) 2020-10-29
EA038421B1 (ru) 2021-08-26
US10464922B2 (en) 2019-11-05
JP6803923B2 (ja) 2020-12-23
TWI623528B (zh) 2018-05-11

Similar Documents

Publication Publication Date Title
MX2018008105A (es) Compuestos inhibidores de metaloenzima.
ECSP22051489A (es) Compuestos inhibidores de metaloenzimas
UY36080A (es) Compuestos inhibidores de metaloenzima como fungicidas.
BR112017002332A2 (pt) terapia de combinação para o tratamento de um paramixovírus
IL269174A (en) Methods for treating complement-mediated diseases and disorders
BR112019006160A2 (pt) composições e métodos para o tratamento das condições oftálmicas
BR112018011709A2 (pt) inibidores bicíclicos de pad4
BR112017007902A2 (pt) composições e métodos para o tratamento de distúrbios do sistema nervoso central.
EA201690007A1 (ru) Соединения, ингибирующие металлоферменты
BR112018010464A8 (pt) formulações farmacêuticas tópicas para tratar condições inflamatórias relacionadas
HK1223093A1 (zh) 杀真菌组合物
MX389663B (es) Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas.
UY37134A (es) Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4
CL2017001046A1 (es) Inhibidoes del bromodominio
BR112017006664A2 (pt) terapias de combinação
BR112016029864A2 (pt) métodos e dispositivos para tratamento de desordens oculares posteriores.
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
BR112012027308A2 (pt) compostos inibidores de metaloenzima
EA201790575A1 (ru) Триазолопиразиноны в качестве ингибиторов pde1
IN2014DN06792A (es)
BR112018001853A2 (pt) métodos para tratamento de um distúrbio e para melhoria do tratamento de um distúrbio
BR112015023207A8 (pt) composições de ci-inh e métodos para prevenção e tratamento de desordens associadas à deficiência de inibidor de c1 esterase.
BR112018000776A2 (pt) métodos para tratamento de câncer usando apilimod
MX2019007892A (es) Compuestos inhibidores de metaloenzimas.
IL255185A0 (en) 1-heteroaryl-indoline-4-carboxamides as modulators of gpr52 useful for the treatment or prevention of disorders related thereto

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: NQP 1598, LTD.

HC Change of company name or juridical status

Owner name: INTERDIGITAL CE PATENT HOLDINGS

FG Grant or registration